Compare Erasca Inc. Common Stock (ERAS) vs Invitation Homes Inc. Common Stock (INVH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Erasca Inc. Common Stock vs Invitation Homes Inc. Common Stock — how do they compare? Erasca Inc. Common Stock trades at $14.6 (market cap $5.17B), while Invitation Homes Inc. Common Stock trades at $26.54 (market cap $15.70B). The key difference: Invitation Homes Inc. Common Stock is far larger — about 3× Erasca Inc. Common Stock's market cap, and Invitation Homes Inc. Common Stock pays a 4.51% dividend while Erasca Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Erasca Inc. Common Stock for 1 Days and Invitation Homes Inc. Common Stock for 0 Days on average.
| ERAS | INVH | |
|---|---|---|
Market Cap | $5.17B | $15.70B |
Volume | 5,313,379 | 4,685,416 |
Sector | Health | Real Estate |
52-Week High | $22.47 | $30.59 |
52-Week Low | $2.20 | $24.39 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $4.95B | $24.16B |
Dividend Yield | — | 4.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ERAS trades at $14.78, down 4.4% today, with a bullish technical signal from moving averages and a consensus analyst price target of $22.50. The company is a clinical-stage oncology firm with no revenue, reporting a net loss of $124.55 million in 2025, but holds significant liquidity and has three potential registration-enabling trials ahead. Recent news highlights FDA Fast Track designation for its lead candidate ERAS-0015.
The outlook is speculative, driven by clinical trial progress; upside exists if trials succeed, but high cash burn and shareholder investigations pose substantial risks. Investment hinges on binary outcomes from drug development, making it suitable only for risk-tolerant investors focused on biotech.
INVH trades at $26.59, down 0.41% on the day, with neutral technical signals and strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue growth from $2.73B in 2025 to $2.9B projected for 2026 supports a solid profit margin expansion to 23.13%. Analyst consensus remains bullish with a $31.67 price target, representing 19% upside potential from current levels.
The investment case centers on INVH's consistent earnings outperformance and robust single-family rental demand, though rising interest rates pose headwinds. With 56% of analysts recommending Buy and institutional accumulation continuing, the stock offers value at current levels despite technical consolidation. Key risks include interest rate sensitivity and regulatory changes affecting institutional homebuying.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Erasca Inc. Common Stock
Erasca is a biotechnology company developing precision medicines for cancer. Its programs target genetic drivers of tumor growth.
Read more on ERAS →About Invitation Homes Inc. Common Stock
Invitation Homes Inc. is a real estate investment trust that acquires, renovates, and leases single-family rental homes across roughly 19 US markets concentrated in Western and Southeastern US. It manages its portfolio through a pod-based local operating model supported by a maintenance technology platform.
Read more on INVH →
